mirikizumab-mrkz (Omvoh)

Indications

• treatment of moderate to severe ulcerative colitis in adults

Contraindications

• hypersentitivity reactions
• avoid live virus vaccines
• active tuberculosis

Dosage

• Prior to Treatment Initiation
  • evaluate patients for tuberculosis infection
  • obtain serum AST, serum ALT & serum bilirubin
  • complete all age-appropriate vaccinations according to guidelines
• 300 mg via intravenous infusion over at least 30 minutes at Weeks 0, 4, & 8
• maintenance dosage is 200 mg via subcutaneous injection
  • given as 2 consecutive injections of 100 mg each at Week 12, & every 4 weeks thereafter

* Intravenous Infusion: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial

* Subcutaneous Injection: 100 mg/mL solution in a single-dose prefilled pen

Adverse effects

• hepatotoxicity
• > 2%: upper respiratory tract infections, arthralgia

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine & inhibits its interaction with the IL-23 receptor

More general terms

• pharmaceutical monoclonal antibody